Table 1.

Patient and tumor characteristics in the entire study population and in relation to completeness of cytoreductive surgery (CRS)^a

	All patients (n = 167) n (%)	Complete CRS (n = 148) n (%)	Incomplete CRS (n = 19)b n (%)	p value
Age: years (IQR)	64 (55–71)	65 (55–71)	59 (55–65)	0.3
Albumin: g/l (IQR)	35.0 (32.0–37.0)	35.0 (32.0–37.0)	33.0 (32.0–36.0)	0.7
BMI (kg/m2)				0.07
< 20.0	1 (0.6)	1 (0.7)	0
20.0–25.0	86 (51.8)	72 (49.0)	14 (73.7)
26.0–30.0	41 (24.7)	36 (24.5)	5 (26.3)
> 30.0	38 (22.9)	38 (25.9)	0
Smoking				0.3
No	141 (85.5)	125 (84.5)	16 (94.1
Yes	24 (14.5)	23 (15.5)	1 (5.9)
ASA score				0.7
10	10 (6.1)	10 (6.8)	0
20	108 (65.5)	95 (64.6)	13 (72.2)
30	46 (27.9)	41 (27.9)	5 (27.8)
40	1 (0.6)	1 (0.7)	0 (0)
FIGO stage				0.6
IIIB	2 (1.2)	2 (1.4)	0
IIIC	86 (51.5)	78 (52.7)	8 (42.1)
IV	79 (47.3)	68 (45.9)	11 (57.9)
Primary treatment				0.3
Primary surgery	86 (51.5)	74 (50.0)	12 (63.2)
NACT	81 (48.5)	74 (50.0)	7 (36.8)
Histology				0.9
HGSC	140 (83.8)	123 (83.1)	17 (89.5)
Endometrioid	3 (1.8)	3 (2.0)	0 (0)
Clear cell	7 (4.2)	6 (4.1)	1 (5.3)
LGSC	14 (8.4)	13 (8.8)	1 (5.3)
Carcinosarcoma	3 (1.8)	3 (2.0)	0 (0)
PCI	22.0 (12.0–27.0)	19.0 (12.0–25.0)	33.0 (30.0–35.0)	< 0.001

IQR, interquartile range; BMI, body mass index; ASA, American Society of Anesthesiology; FIGO, International Federation of Gynecology and Obstetrics; NACT, neoadjuvant chemotherapy; HGSC, high-grade serous adenocarcinoma; LGSC, low-grade serous adenocarcinoma

^aPercentages are presented in relation to available information. Missing information in 0–6 of variables. Statistics were obtained by independent t tests or Chi square tests

^bIncomplete CRS is defined as Completeness of Cytoreductive Score (CCS) 2 or 3